Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer

NCT02125175 is registered in ClinicalTrials.gov with The Clatterbridge Cancer Centre NHS Foundation Trust as lead sponsor.

NCT NCT02125175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer
Lead sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2014
Completion date
September 30, 2019
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer